Viatris Inc.

VTRS

$16.94

-0.88%

2026-09-03 16:00:00 EDT-$0.15

Healthcare

Drug Manufacturers - Specialty & Generic

NASDAQ

Active Trading

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater ...

Price Action of VTRS

$16.94

-0.88%-$0.15

High—

Low—

52W High-7.2%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

Viatris Inc. is a global pharmaceutical and healthcare enterprise formed in November 2020 through the merger of Mylan and Upjohn, a legacy division of Pfizer. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a ...Viatris Inc. is a global pharmaceutical and healthcare enterprise formed in November 2020 through the merger of Mylan and Upjohn, a legacy division of Pfizer. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive portfolio encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs), targeting a wide array of therapeutic areas, including noncommunicable and infectious diseases. Its biosimilars focus on oncology, immunology, endocrinology, ophthalmology, and dermatology. Viatris's APIs serve numerous drug categories, such as antibacterials, central nervous system agents, cardiovascular drugs, antivirals, and proton pump inhibitors. Beyond manufacturing, the company supports patient health through services like diagnostic clinics and digital tools. Products are distributed globally to retail pharmacies, wholesalers, government bodies, and healthcare institutions via traditional and e-commerce channels. Notable brands include Lyrica, Lipitor, Creon, EpiPen, Viagra, and biosimilars like Fulphila and Ogivri. Viatris fosters innovation through collaborations with partners such as Biocon and Fujifilm Kyowa Kirin Biologics. With a workforce of around 30,000 and headquartered in Canonsburg, Pennsylvania, Viatris generated approximately US$14.7 billion in revenue in 2024, demonstrating its significant global footprint.ExpandCollapse

Founded

1961

Employees

30000

CEO

Scott Andrew Smith

Full Name

Viatris Inc.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

ROE

-2.79%

Market Cap

$19.73B

Current Ratio

1.58

WACC

6.54%

ROIC

-0.20%

Contact Information

https://www.viatris.com

724 514 1800

Robert J. Coury Global Center, Canonsburg, PA 15317

Key Metrics of VTRS

Snapshot

Latest / TTM · 6 periods

Market Cap

$19.73B

ROCE

-0.3%

EV / EBITDA

12.32x

+8.5% YoY

FCF Yield

9.5%

-3.8% YoY

Cash Conversion Cycle

193.2d

Current Ratio

1.58

Quick take

TTM —

Positive CCC

Financial Highlights of VTRS

Profitability trend

Latest / TTM · 6 periods

Gross Margin

34.8%

Net Margin

-2.8%

P/E Ratio

-47.22x

n/a

Debt / Equity

0.96

n/a

Current Ratio

1.58

Dividend Yield

2.8%

Understanding

TTM —

Interest coverage is weak

Calendar of VTRS

Upcoming

Sep 16, 2026In 12 days
Dividend payment
$0.48 per share
Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $0.65 · Revenue $3.81B · 5 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $0.59 · Revenue $3.72B · 5 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $2.50 · Revenue $14.78B · 5 analysts

Recent history

Aug 21, 2026
Ex-dividend date
$0.48 per share
Aug 6, 2026
Q2 FY2026 · Results reported
EPS $-0.10 · Revenue $3.76B
View filing
May 7, 2026
Q1 FY2026 · Results reported
EPS $0.15 · Revenue $3.52B
View filing
Feb 26, 2026
FY2025 · Annual results
EPS $-3.00 · Revenue $14.30B
View filing
Nov 6, 2025
Q3 FY2025 · Results reported
EPS $-0.11 · Revenue $3.76B
View filing
Aug 7, 2025
Q2 FY2025 · Results reported
EPS $-0.00 · Revenue $3.58B
View filing

Financial Statements of VTRS

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$14.3B	-3.0%	+6.8%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-3.5B	-454.2%	-167.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+35.1%	-8.1%	+17.8%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-18.6%	-27277.5%	+107.4%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-24.6%	-471.3%	-163.0%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$1.9B	-2.0%	-5.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+13.5%	+1.0%	-11.6%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	99.9%	+30.2%	-4.1%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	1.30x	-21.1%	-1.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$37.2B	-10.4%	-4.9%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-3.00 vs 2.32	-229.5%	-0.10 vs 0.60	-116.6%
Revenue Surprise	$14.3B vs $14.1B	+1.2%	$3.8B vs $3.7B	+2.2%

Insider Transactions of VTRS

Acquisitions (A)

Since Apr 15, 2026

Disposals (D)

Since Apr 15, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 15, 2026	Enrietti Andrew	officer: See Remarks	Common Stock	A	25,134	—
Aug 15, 2026	Enrietti Andrew	officer: See Remarks	Common Stock	A	999	—
Aug 15, 2026	Enrietti Andrew	officer: See Remarks	Common Stock	D	435	$16.23
Aug 15, 2026	Enrietti Andrew	officer: See Remarks	Common Stock	D	10,931	$16.23
Aug 15, 2026	Enrietti Andrew	officer: See Remarks	Restricted Stock Units	D	25,134	—

Earnings Call Transcript of VTRS

1 transcript segments

Q2 2026

Unknown Speaker

Operator : Good morning, everyone, and welcome to the Viatris Q2 2026 Earnings Call. [Operator Instructions] Please also note today's event is being recorded. At this time, I'd like to turn the floor over to Bill Szablewski, Head of Capital Markets. Sir, please go ahead. William Szablewski : Good morning, everyone. Welcome to our Q2 2026 earnings call. With us today is CEO, Scott Smith; Interim CFO, Paul Campbell; Chief R&D Officer, Philippe Martin; and Chief Commercial Officer, Corinne Le Goff. During today's call, we will be making forward-looking statements on a number of matters, including our financial guidance for 2026 and various strategic initiatives. These statements are subject to risks and uncertainties. We will also be referring to certain actual and projected non-GAAP financial measures. Please refer to today's slide presentation and our SEC filings for more information, including reconciliations of those non-GAAP measures to most directly comparable GAAP measures. When discussing 2026 actual or reported results, we will be making certain comparisons to 2025 actual or reported results on an operational basis, which excludes the impact of foreign currency rates. When comparing our 2026 actual or reported results to our expectations, we are making comparisons to our 2026 financial guidance. With that, I'll hand the call over to our CEO, Scott Smith. Scott Smith : Good morning, everyone. We're off to an exceptional start in 2026. We delivered another strong quarter that reinforces our confidence in the strategy we outlined earlier this year. In the second quarter, we delivered $3.8 billion in total revenues, representing 3.5% operational revenue growth year-over-year, adjusted EBITDA of $1.2 billion and adjusted EPS of $0.69 per share. These results exceeded our expectations and reflect the strong momentum across our businesses and continued improvement in operating leverage. Just as importantly, these results give us confidence to raise our outlook for the remainder of the year. Let me briefly highlight some of the progress we've made across our businesses. Commercial execution was excellent across our global portfolio during the quarter, led once again by Greater China, where the commercial investments in our portfolio of established brands are generating meaningful growth. In North America, execution across our complex generics and transdermal products also drove solid growth. Our pipeline is progressing as expected. As we announced last week, we received U.S. regulatory approval for Gwyn Lo and expect to launch the product later this year. At the same time, launch preparations continue for fast-acting meloxicam as it progresses through FDA review. We're confident in the differentiated clinical profiles of both medicines and also in our commercial readiness. In Japan, we recently reported Phase III results for Nefecon, while pitolisant continues to progress through the final stages of regulatory review, underscoring the momentum …

Leadership Team of VTRS

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Scott Andrew Smith	Chief Executive Officer & Director	USD 5,123,318	Male	1962	Active
Paul Campbell	Interim CFO, Chief Accounting Officer & Corporate Controller	USD 3,702,783	Male	1967	Active
Corinne Le Goff	Chief Commercial Officer	USD 2,334,887	—	1965	Active
Matthew Joseph Maletta	Chief Legal Officer	USD 2,214,300	Male	1972	Active
Andrew Enrietti	Chief Administrative & Transformation Officer	USD 1,940,545	Male	1985	Active
Ramkumar V. Rayapureddy	Chief Information Officer	—	Male	—	Active
Peter McCormick	Chief Supply Officer	—	Male	—	Active
Philippe Martin	Chief R&D Officer	—	Male	1976	Active
William Szablewski	Head of Investor Relations & Capital Markets	—	Male	—	Active
Lara Ramsburg	Chief People & Corporate Affairs Officer	—	Female	—	Active

Recent News of VTRS

Seeking Alpha8/6/2026Neutral

Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript

GuruFocus8/6/2026Neutral

Viatris Inc (VTRS) Shares Fall 7.6% -- GF Value Says Still Overvalued

On August 06, 2026, Viatris Inc (VTRS) shares fell 7.6%, closing at $16.29. Over the past year, the stock has seen significant volatility, with a 52-week high o

Benzinga8/6/2026Neutral

Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook

Harrow Inc. (NASDAQ:HROW) on Thursday agreed to acquire Tyrvaya (varenicline solution) nasal spray 0.03 mg from Viatris Inc. (NASDAQ:VTRS).

Zacks Investment Research8/6/2026Neutral

VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump

Viatris tops Q2 earnings and revenue estimates as Greater China sales surge 21%, helping lift results and prompting a higher 2026 financial outlook.

Zacks Investment Research8/6/2026Neutral

Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Viatris (VTRS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Historical Employee Count of VTRS

Current

30,000

Change

-6.25%

Minimum

30,000

Maximum

38,000

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	30,000	10-K	Feb 26, 2026	View
Dec 31, 2024	32,000	10-K	Feb 27, 2025	View
Dec 31, 2023	38,000	10-K	Feb 27, 2024	View
Dec 31, 2023	38,000	10-K	Feb 28, 2024	View
Dec 31, 2022	37,000	10-K	Feb 27, 2023	View
Dec 31, 2021	37,000	10-K	Feb 28, 2022	View

Related stocksDrug Manufacturers - Specialty & Generic

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Viatris Inc.